PHILADELPHIA, July 23, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential breaches of fiduciary duty claims involving certain officers and/or directors of Acer Therapeutics, Inc. (“Acer” or the “Company”) (NASDAQ: ACER).
The investigation concerns, among other things, whether certain Acer officers and/or directors made materially false and misleading statements and/or failed to disclose material information regarding, among other things, the Company’s business, operational, and compliance policies and whether Acer lacked sufficient data to support filing EDSIVO’s (celiprolol) New Drug Application (“NDA”) with the FDA for the treatment of Ehlers-Danlos Syndrome (“vEDS”).
Investors who have owned Acer stock continuously since at least September 25, 2017 are encouraged to contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, securities@kehoelawfirm.com, info@kehoelawfirm.com, to discuss the investigation or potential legal claims.
Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.
This press release may constitute attorney advertising.